Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • The Great Wealth Transfer: Women at the Center of Wealth Stewardship

    As trillions of dollars change hands, women are taking on a more central role in managing, preserving, and passing on wealth.

    Read more

  • Obsidian Therapeutics, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Obsidian Therapeutics, Inc. (OBX $16.82). Obsidian is developing amsoki-cel (OBX-115), an engineered tumor-infiltrating lymphocyte (TIL) therapy for the treatment of oncology conditions.

    Read more

  • VWE Automotive Has Agreed to be Acquired by Main Capital Partners

    William Blair acted as exclusive financial advisor to VWE Automotive, a portfolio company of NewPort Capital, in connection with its pending sale to Main Capital Partners.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures